GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Merck & Co MRK · USD

Health Care · Pharmaceuticals · US listing · 🇺🇸 United States

S&P 500Dow Jones

Compare

148.76

+1.38%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

35 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 8Strong buy
  • 17Buy
  • 10Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Last close 148.76Average target 140.42

Low
105.00
Average
140.42
Median
144.00
High
155.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$67.02bn$69.81bn$74.08bn$74.36bn$74.90bn
Revenue, highest$67.18bn$71.81bn$79.99bn$76.48bn$77.03bn
Revenue, lowest$66.75bn$68.90bn$70.34bn$72.75bn$73.27bn
Earnings per share2.639.2110.179.969.88
Earnings per share, highest2.749.9511.2710.3210.24
Earnings per share, lowest2.498.498.119.689.60
Analysts171619915

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Forecast2.10-0.27-1.522.032.372.032.161.63
Reported2.49-0.13-1.282.092.682.192.221.72
Difference+18.5%+52.3%+16.0%+3.0%+13.1%+7.7%+2.9%+5.4%

Rating changes

Latest broker notes

  • Daiwa CapitalNeutral → Outperform
  • Argus ResearchBuy
  • GuggenheimBuy
  • BarclaysOverweight
  • JP MorganOverweight
  • GuggenheimBuy
  • BMO CapitalOutperform
  • Morgan StanleyEqual Weight
  • Wells FargoOverweight
  • RBC CapitalOutperform
  • Cantor FitzgeraldNeutral
  • ScotiabankSector Outperform

Recent targets

Latest 12 months

  • Berenberg Bank137.00
  • HSBC172.00
  • Leerink Partners161.00
  • Guggenheim170.00
  • Wells Fargo170.00
  • Argus Research170.00
  • Wolfe Research180.00
  • Goldman Sachs160.00

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

7 / 10

Revenue growth 5.1% a year over 10 years. Return on equity 34.7%.

Model fair value

300.05

From earnings 300.05, from revenue 112.23.

Piotroski score

4 / 9

A nine-point test of financial strength, for 31 Dec 2025.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.